新的药物组合在两个方面攻击前列腺癌,让男性保持更长时间的健康

2021年7月8日

 

研究负责人 Johann de Bono 教授
研究负责人 Johann de Bono 教授

An important new trial shows that by combining the existing targeted drug abiraterone with a new experimental drug, the growth signals of two cancers can be blocked at the same time, which can more effectively treat patients with special invasions Men with sexual prostate cancer.

The results of the Lancet, IPATential150 study published today show that this new combination extends the time for prostate cancer to progress and spread further in men lacking the PTEN gene (one of the most common missing tumor suppressor genes in cancer).

A team led by the Royal Marsden Hospital and the Cancer Institute UK evaluated the targeted hormone drug abiraterone (the standard drug for many men with advanced prostate cancer) and a new drug called ipatasertib for advanced patients who had not previously been treated The curative effect of men suffering from prostate cancer.

Previous results on the safety and effectiveness of the combined use of ipatasertib and abiraterone have shown promise, and these latest findings provide the first strong evidence of the benefits of the combined use of these two drugs.

The international phase III trial was conducted at 200 locations in 26 countries/regions and involved 1,101 men, of which 521 had tumors lacking a fully functional PTEN gene.

It was found that compared with abiraterone alone, the administration of ipatasertib plus abiraterone as a first-line treatment can reduce the risk of death or cancer progression in patients with tumors lacking PTEN by 23%. 61% of patients receiving the combination therapy found that their tumors had become smaller - compared with 39% of patients taking abiraterone alone. In addition, 19% of patients taking the combination medication had a complete remission-which means that the signs of the disease were missing-compared with 6% of patients taking only abiraterone.

大约一半患有晚期前列腺癌的男性患有 PTEN 基因有缺陷的肿瘤,而这组患者的预后往往特别差。这项新的 III 期试验可以开辟联合治疗作为一种新的有针对性的方法,使这些患者保持更长时间的健康,每年可能使英国超过 10,000 名男性受益。

ipatasertib 和阿比特龙的组合还与更高和更持久的 PSA 反应率相关 - 它用于监测前列腺癌进展 - 无论有无 PTEN 的患者。

这种药物组合的作用是同时关闭两种促进前列腺癌的强大生长信号。阿比特龙阻断雄激素受体的信号传导,而 ipatasertib 阻断另一组涉及蛋白质 AKT 的肿瘤生长信号。

研究带头人 约翰·德博诺教授,皇家马斯登的肿瘤学专家和英国癌症研究院的实验癌症医学教授说:

“我们已经证明,将一种现有药物和一种新药物结合起来在两个不同的方面攻击癌症,可以使前列腺癌患者更健康更长时间。这些发现为患有常见和侵袭性前列腺癌的患者提供了一种有希望的新治疗选择,并最终可能改变这些针对这些男性的临床操作。

“PTEN 是前列腺癌中最常缺失的基因之一,因此这项研究为许多患者带来了希望。”

来自 Market Harborough 的 68 岁的 Peter Hartley 在诊断出前列腺癌后,已经通过 IPATential150 试验在皇家马斯登接受治疗三年。在这项研究试验中,彼得的前列腺特异性抗原 (PSA) 水平迅速下降,肿瘤缩小,使他能够保持健康的生活。彼得说:

“当我在 2015 年 6 月第一次被诊断出患有晚期前列腺癌时,他们告诉我他们无能为力,我只剩下两到三年的时间了,这是在我来到皇家马斯登之前。化疗后,我加入了德博诺教授的研究试验,在过去的三年里,我重获新生。参加这次试验简直就是一个奇迹,我没有任何副作用,而且我的生活质量非常好。

“我感到非常荣幸和幸运能有这个机会,使我得以尽可能长时间地保持健康。我的医疗团队密切关注我,并定期接受医院检查,这令人放心。护士和医生都很棒,不辞辛苦尽可能给我最多的照顾。由于这种治疗的成功,我可以继续做我喜欢做的事情,比如和我的妻子、孩子和 3 个孙子共度时光,去湖区游玩,享受我的高尔夫、网球和徒步旅行!”

彼得哈特利
彼得哈特利

IPATential150 试验由罗氏资助。

 

欲了解更多信息,请联系中国国际患者部邮箱:Advisor.IPC@rmh.nhs.uk 或致电 020 7811 8690 (可提供中文服务)